Molecular markers in well-differentiated thyroid cancer
Language English Country Germany Media print-electronic
Document type Journal Article, Review
    PubMed
          
           29626249
           
          
          
    DOI
          
           10.1007/s00405-018-4944-1
           
          
          
      PII:  10.1007/s00405-018-4944-1
  
    Knihovny.cz E-resources
    
  
              
      
- Keywords
- Adenocarcinoma, follicular, Carcinoma, papillary, NIFTP, Thyroid neoplasm/diagnosis, Thyroid neoplasm/genetics, miRNA,
- MeSH
- Biomarkers metabolism MeSH
- Carcinoma genetics metabolism pathology MeSH
- Humans MeSH
- Mutation genetics MeSH
- Thyroid Neoplasms genetics metabolism pathology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Biomarkers MeSH
PURPOSE: Thyroid nodules are of common occurrence in the general population. About a fourth of these nodules are indeterminate on aspiration cytology placing many a patient at risk of unwanted surgery. The purpose of this review is to discuss various molecular markers described to date and place their role in proper perspective. This review covers the fundamental role of the signaling pathways and genetic changes involved in thyroid carcinogenesis. The current literature on the prognostic significance of these markers is also described. METHODS: PubMed was used to search relevant articles. The key terms "thyroid nodules", "thyroid cancer papillary", "carcinoma papillary follicular", "carcinoma papillary", "adenocarcinoma follicular" were searched in MeSH, and "molecular markers", "molecular testing", mutation, BRAF, RAS, RET/PTC, PAX 8, miRNA, NIFTP in title and abstract fields. Multiple combinations were done and a group of experts in the subject from the International Head and Neck Scientific Group extracted the relevant articles and formulated the review. RESULTS: There has been considerable progress in the understanding of thyroid carcinogenesis and the emergence of numerous molecular markers in the recent years with potential to be used in the diagnostic algorithm of these nodules. However, their precise role in routine clinical practice continues to be a contentious issue. Majority of the studies in this context are retrospective and impact of these mutations is not independent of other prognostic factors making the interpretation difficult. CONCLUSION: The prevalence of these mutations in thyroid nodule is high and it is a continuously evolving field. Clinicians should stay informed as recommendation on the use of these markers is expected to evolve.
Department of Pathology Charles University Faculty of Medicine in Plzen Plzen Czech Republic
Department of Pathology The University of Texas MD Anderson Cancer Center Houston TX USA
Department of Pathology University of Arkansas for Medical Sciences Little Rock AR USA
Department of Surgery and Surgical Ethics The University of Chicago Medicine Chicago IL USA
Departments of Surgery and Otolaryngology Head and Neck Surgery Edinburgh University Edinburgh UK
Head and Neck Service Memorial Sloan Kettering Cancer Center New York NY USA
Head Neck Services Tata Memorial Hospital Parel Mumbai 400012 India
International Head and Neck Scientific Group Padua Italy
See more in PubMed
Hum Pathol. 2016 Aug;54:134-42 PubMed
Cancer. 2012 Apr 1;118(7):1764-73 PubMed
Cancer. 2014 Dec 1;120(23 ):3627-34 PubMed
Arch Pathol Lab Med. 2011 May;135(5):569-77 PubMed
Am J Clin Pathol. 2003 Jul;120(1):71-7 PubMed
Cell. 2014 Oct 23;159(3):676-90 PubMed
Ann Surg Oncol. 2013 Jan;20(1):47-52 PubMed
Endocr Pathol. 2002 Spring;13(1):3-16 PubMed
Thyroid. 2009 Dec;19(12 ):1351-61 PubMed
Thyroid. 2016 Jul;26(7):911-5 PubMed
J Clin Endocrinol Metab. 2006 Sep;91(9):3603-10 PubMed
Ann Surg Oncol. 2009 Feb;16(2):240-5 PubMed
Cancer. 2007 Jul 1;110(1):38-46 PubMed
Histopathology. 2018 Jan;72 (1):6-31 PubMed
Thyroid. 2000 Jan;10(1):19-23 PubMed
Otolaryngol Clin North Am. 2014 Aug;47(4):557-71 PubMed
Endocr Relat Cancer. 2015 Apr;22(2):159-68 PubMed
Int J Clin Exp Med. 2013;6(1):74-80 PubMed
N Engl J Med. 2016 Aug 18;375(7):614-7 PubMed
N Engl J Med. 2012 Aug 23;367(8):705-15 PubMed
J Clin Oncol. 2015 Jan 1;33(1):42-50 PubMed
Cancer Cytopathol. 2017 May;125(5):323-331 PubMed
J Clin Endocrinol Metab. 2000 Mar;85(3):1170-5 PubMed
Otolaryngol Clin North Am. 2014 Aug;47(4):573-93 PubMed
Clin Endocrinol (Oxf). 1999 Apr;50(4):529-35 PubMed
J Clin Endocrinol Metab. 2001 Jul;86(7):3211-6 PubMed
Nat Rev Cancer. 2013 Mar;13(3):184-99 PubMed
Clin Cancer Res. 2000 Mar;6(3):1093-103 PubMed
Am J Surg Pathol. 2006 Feb;30(2):216-22 PubMed
J Clin Endocrinol Metab. 2007 Nov;92(11):4085-90 PubMed
JAMA Oncol. 2016 Aug 1;2(8):1023-9 PubMed
Curr Opin Otolaryngol Head Neck Surg. 2013 Apr;21(2):135-42 PubMed
Ann Surg Oncol. 2010 Dec;17(12):3294-300 PubMed
J Clin Endocrinol Metab. 2001 May;86(5):2187-90 PubMed
Cancer. 2009 Jun 25;117(3):195-202 PubMed
J Clin Endocrinol Metab. 2015 Jul;100(7):2743-50 PubMed
Cancer Med. 2015 Jun;4(6):791-9 PubMed
Thyroid. 2016 Jan;26(1):1-133 PubMed
Endocr Connect. 2017 Apr;6(3):R8-R17 PubMed
Am J Clin Pathol. 2009 Nov;132(5):658-65 PubMed
Science. 2000 Aug 25;289(5483):1357-60 PubMed
Ann Surg. 2007 Sep;246(3):466-70; discussion 470-1 PubMed
J Clin Endocrinol Metab. 1999 Nov;84(11):4232-8 PubMed
J Clin Endocrinol Metab. 1997 Apr;82(4):1306-7 PubMed
Hum Pathol. 2014 Jul;45(7):1339-47 PubMed
Endocr Pract. 2014 Apr;20(4):360-3 PubMed
J Clin Endocrinol Metab. 2013 Nov;98(11):E1852-60 PubMed
J Clin Invest. 2016 Mar 1;126(3):1052-66 PubMed
Endocrinol Metab (Seoul). 2015 Sep;30(3):252-62 PubMed
J Clin Oncol. 2003 Sep 1;21(17):3226-35 PubMed
J Clin Pathol. 2017 Jun;70(6):500-507 PubMed
J Clin Endocrinol Metab. 2006 Jan;91(1):213-20 PubMed
J Clin Endocrinol Metab. 2012 Jun;97(6):1905-12 PubMed
Thyroid. 2011 Mar;21(3):243-51 PubMed
Cancer Cytopathol. 2016 Oct;124(10 ):711-721 PubMed
J Clin Endocrinol Metab. 2008 Oct;93(10):3943-9 PubMed
Endocr Relat Cancer. 2006 Jun;13(2):497-508 PubMed
Arch Pathol Lab Med. 2016 Dec;140(12 ):1338-1344 PubMed
J Clin Endocrinol Metab. 2012 Dec;97(12):4390-8 PubMed
J Clin Endocrinol Metab. 2005 Dec;90(12):6373-9 PubMed
Thyroid. 2015 Jul;25(7):716-59 PubMed
Thyroid. 2017 Nov;27(11):1341-1346 PubMed
J Clin Endocrinol Metab. 2003 Sep;88(9):4440-5 PubMed
Endocr Pract. 2017 Aug;23 (8):979-988 PubMed
J Natl Cancer Inst. 2003 Apr 16;95(8):625-7 PubMed
Thyroid. 2017 Apr;27(4):506-511 PubMed
Arch Intern Med. 1994 Aug 22;154(16):1838-40 PubMed
JAMA. 2013 Apr 10;309(14):1493-501 PubMed
Cancer. 2018 Apr 15;124(8):1682-1690 PubMed
Endocr Relat Cancer. 2013 Jul 12;20(4):603-10 PubMed
Head Neck. 2013 Oct;35(10):1499-506 PubMed
Medicine (Baltimore). 2012 Sep;91(5):274-86 PubMed
J Clin Endocrinol Metab. 2013 May;98(5):E914-22 PubMed
J Clin Endocrinol Metab. 2008 May;93(5):1600-8 PubMed
J Clin Endocrinol Metab. 2011 Nov;96(11):3390-7 PubMed
Cancer Res. 2008 Jun 1;68(11):4183-91 PubMed
Cancer Cytopathol. 2016 Sep;124(9):616-20 PubMed
Head Neck. 2010 Jan;32(1):38-45 PubMed
Adv Anat Pathol. 2001 Nov;8(6):345-54 PubMed
MicroRNA Deregulation in Papillary Thyroid Cancer and its Relationship With BRAF V600E Mutation
